Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30718706 | 1.00 | CYP2A6 (0.46) | CYP2A6ABL1KDM4EMEN1ALDH1A1 | |
| SCHEMBL6833006 | 0.92 | GSK3A (0.49) | CYP2A6ABL1KDM4EMEN1ALDH1A1 | |
| SCHEMBL31263588 | 0.92 | GSK3A (0.49) | CYP2A6ABL1KDM4EMEN1ALDH1A1 | |
| SCHEMBL10976089 | 0.78 | CYP2A6 (0.50) | CYP2A6ABL1NOS1DYRK1AGRM4 | |
| SCHEMBL10024955 | 0.75 | ALDH1A1 (0.46) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8268451 | 0.75 | CYP1A2 (0.54) | CYP2A6ABL1KDM4EALDH1A1KMT2A | |
| SCHEMBL269264 | 0.75 | CYP2A6 (0.57) | CYP2A6ABL1KDM4EMEN1ALDH1A1 | |
| SCHEMBL17336629 | 0.75 | NOS1 (0.38) | ABL1MAPTNOS1GRM4CYP3A4 | |
| SCHEMBL10978740 | 0.75 | L3MBTL1 (0.50) | CYP2A6ABL1KDM4EALDH1A1MAPT | |
| SCHEMBL16295919 | 0.75 | CYP1A2 (0.46) | ABL1MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113877483-B | Low-temperature continuous synthesis device and method for pharmaceutical intermediate halogenated isoquinoline boric acid | 烟台宁远药业有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-113877483-A | Low-temperature continuous synthesis device and method for pharmaceutical intermediate halogenated isoquinoline boric acid | 烟台宁远药业有限公司 | 2022-01-04 | — | — | CN | claimed |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | IP2IPO INNOVATIONS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-115427035-B | ENL/AF9 YEATS inhibitors | 洛克菲勒大学 | 2025-04-22 | — | — | CN | disclosed |
| EP-4522610-A1 | GCN2 INHIBITORR | IP2IPO Innovations Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| CN-119451955-A | GCN2 inhibitors | IP2IPO创新有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119325469-A | WEE1 degrading compounds and uses thereof | 百时美施贵宝公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| EP-2771004-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| WO-2014044846-A1 | 3-(ARYL- OR HETEROARYL-AMINO)-7-(3,5-DIMETHOXYPHENYL)ISOQUINOLINE DERIVATIVES AS FGFR INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS OR DYSPLASIA | EVOTEC (UK) LTD. (GB) | 2014-03-27 | — | — | WO | disclosed |
| EP-2632925-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2013-09-04 | — | — | EP | disclosed |
| CN-103189377-A | N1/n2-lactam acetyl-coa carboxylase inhibitors | PFIZER | 2013-07-03 | — | — | CN | disclosed |
| WO-2013062900-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| WO-2012056372-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | EIF2AK4, GCN1, GCGR | CYP2A6 259/4885ABL1 2057/4885KDM4E 3081/4885 |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | CYP2A6 987/4885ABL1 3680/4885KDM4E 2570/4885 |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | CYP2A6 343/4885ABL1 32/4885KDM4E 3835/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | CYP2A6 4656/4885ABL1 2278/4885KDM4E 311/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | CYP2A6 3134/4885ABL1 116/4885KDM4E 1748/4885 |
| US-12384789-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | CYP2A6 2077/4885ABL1 2222/4885KDM4E 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.